Misplaced Pages

Revision as of 12:07, 17 March 2021

This article has not yet been rated on Misplaced Pages's content assessment scale. It is of interest to the following WikiProjects:

Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details. COVID-19 Mid‑importance This article is within the scope of WikiProject COVID-19, a project to coordinate efforts to improve all COVID-19-related articles. If you would like to help, you are invited to join and to participate in project discussions.COVID-19Wikipedia:WikiProject COVID-19Template:WikiProject COVID-19COVID-19 Mid This article has been rated as Mid-importance on the project's importance scale. Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details. Medicine Mid‑importance This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Misplaced Pages talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine Mid This article has been rated as Mid-importance on the project's importance scale. Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details. Pharmacology Mid‑importance This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Misplaced Pages. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology Mid This article has been rated as Mid-importance on the project's importance scale.

|topic= not specified. Available options:

Data behind the vaccine

https://www.wired.com/story/the-astrazeneca-covid-vaccine-data-isnt-up-to-snuff/

Where to add this? TrangaBellam (talk) 07:51, 1 January 2021 (UTC)

It's not WP:MEDRS so not really useful for anything biomedical; maybe useful for something on the (mis)handling of the various announcements, but possibly at AstraZeneca rather than here. Alexbrn (talk) 11:57, 1 January 2021 (UTC)

I don't think the causes for Misplaced Pages:Identifying_reliable_sources_(medicine)#Popular_press apply here. It is the very evidence quality, which is assessed. The author is Hilda Bastian, integrally associated with Cochrane. TrangaBellam (talk) 15:55, 1 January 2021 (UTC)

Yes, we need something rather better than an article in Wired for an assessment of evidence quality, especially in this subject area where sanctions are in effect. Alexbrn (talk) 16:17, 1 January 2021 (UTC)

Article title

Should we rename this one Covishield? ,Crookesmoor (talk) 10:33, 3 January 2021 (UTC)

As of now, I oppose moving this article to "Covishield". From what I could gather, that name recently started to be referenced by Media in India (See ). If someone can find any source be the University of Oxford and/or AstraZeneca with that name, please let me know, as I can't find any yet. Anyway, even if "Covishield" comes to be the commercial name of this vaccine, the page should be moved to have the name of the pharmaceutical name of the substance (See: (International nonproprietary name (INN))), not the commercial name (See: Gam-COVID-Vac for "Sputnik V" and Tozinameran for "Comirnaty"). ACLNM (talk) 01:29, 4 January 2021 (UTC)

1. ^ "Hindustan Times".
2. "The Times of India".
3. "The Hindu".

• No, per WP:MEDTITLE. Alexbrn (talk) 03:33, 4 January 2021 (UTC)

Too soon to move this page? New discussion on 05 January 2021

There has been some traction (mainly in Indian media, from what I could find) to start calling this vaccine by the name "Covishield". Even yesterday I opposed the adoption of that name, defending that the page should only be moved once the pharmaceutical name of the vaccine's active component(s) is established. I was now scrolling through AstraZeneca's press releases and I found this press release ; according to it, they themselves refer to their own vaccine by the name "COVID-19 Vaccine AstraZeneca, formerly AZD1222". I can't find yet the International nonproprietary name (INN) for this vaccine, so I suppose it is not yet established/public. I propose that, before we move the page to any of the commercial names, we wait at least a few weeks for new developments, especially regarding the INN and/or the substance's official name. ACLNM (talk) 02:45, 5 January 2021 (UTC)

1. "The Times of India".
2. "The Hindu".
3. "Hindustan Times".
4. "AstraZeneca's COVID-19 vaccine authorised for emergency supply in the UK". AstraZeneca. 30 December 2020. Retrieved 5 January 2021. The UK has provided authorisation for emergency supply of COVID-19 Vaccine AstraZeneca, formerly AZD1222, for the active immunisation of individuals 18 years or older.

Half-first-dose issue

I was wondering what happened with the issue of whether a first half-dose is better than a full first dose or not. I found the following article that claims that the 90-percent efficacy rate for the first half-dose did not hold up under further analysis—the higher success rate may have been due to a longer gap between the two doses. Gabn1 (talk) 13:36, 22 January 2021 (UTC)

Would need WP:MEDRS (and then there's the question of what "better" means; better for an individual, or better for society?) Alexbrn (talk) 13:46, 22 January 2021 (UTC)

A Commons file used on this page or its Wikidata item has been nominated for deletion

The following Wikimedia Commons file used on this page or its Wikidata item has been nominated for deletion:

• AstraZeneca COVID-19 Vaccine (cropped).jpg

Participate in the deletion discussion at the nomination page. —Community Tech bot (talk) 00:07, 23 January 2021 (UTC)

95% effectiveness, if the 2 shots are separated by 3 months?

"2 min read. Updated: 29 Dec 2020, 07:23 AM IST

Title: Efficacy of Oxford jabs at 95% if given 3 months apart: SII.

AstraZeneca will soon release data showing that the effectiveness of its covid-19 vaccine rises to as much as 95% if the two shots are separated by about 2-3 months, said Adar Poonawalla, chief executive of Serum Institute of India (SII), the British company’s manufacturing partner".

https://www.livemint.com/science/health/efficacy-of-oxford-jabs-at-95-if-given-3-months-apart-sii-11609181643451.html

Yes I know 3 months is a too long time in this covid fight, or is it? With 1 months the efficacy is much lower, so why not wait for 2 more months?

--ee1518 (talk) 14:12, 24 January 2021 (UTC)

Is this a type of DNA vaccine?

Per Talk:COVID-19 vaccine#Missing link to DNA vaccine, is this drug classed as a DNA vaccine?

I was not sure, but if it is, we should state it in the description (and update the DNA vaccine article)? Britishfinance (talk) 20:11, 24 January 2021 (UTC)

• I would say the key point is "replication-deficient simian adenovirus vector" is not wikilinked or otherwise defined. replication-deficient->(Deficient in replication) simian->Simian adenovirus->adenovirus vector->Viral vector .... not my area so I'm not touching it.Djm-leighpark (talk) 20:32, 24 January 2021 (UTC)

@Britishfinance It is not a DNA vaccine but explaining that the mechanism is, as for DNA vaccines, to bring a DNA strand encoding the Spike into the cell nucleus, is a good idea. Adding an Adenovirus-vector section into the DNA vaccine article (explaining the same) is not a bad idea neither. 2A01:E0A:852:9590:854A:FE19:B4A0:45F7 (talk) 13:28, 26 January 2021 (UTC)

Production

The “Production and Supply” section doesn’t actually have anything about production in it. AFAIK the production is at a number of plants in India, Europe and the UK. Would be good to flesh that out. Fig (talk) 09:18, 26 January 2021 (UTC)

Involvement of Bill Gates Foundation

This article seem to indicate that Oxford reversed its original position on pricing the vaccine, on the urging of Bill Gates. — Preceding unsigned comment added by 124.168.29.8 (talk) 16:25, 26 January 2021 (UTC)

More up-to-date. Alexbrn (talk) 16:32, 26 January 2021 (UTC)

EU press briefing

Press briefing on EU recommendation for COVID-19 Vaccine AstraZeneca
Live broadcast - 15:00 - 15:45 CET
Date: 29 January 2021
This virtual press briefing will discuss the outcome of the evaluation of COVID-19 Vaccine AstraZeneca by EMA’s human medicines committee (CHMP).

https://www.ema.europa.eu/en/events/press-briefing-eu-recommendation-covid-19-vaccine-astrazeneca

--Whywhenwhohow (talk) 05:47, 29 January 2021 (UTC)

Useful link to Covax Oxford vaccine distribution

Here is a link to a useful page setting out Covax's vaccine distribution program with the help of the Serum Institute of India and SK Bioscience of South Korea. I don't have time to add relevant info to this page, but thought I'd share the link: https://www.gavi.org/sites/default/files/covid/covax/COVAX-Interim-Distribution-Forecast.pdf Jopal22 (talk) 14:45, 3 February 2021 (UTC)

South Africa stops rollout

"Rollout of AstraZeneca Covid-19 Vaccine Halted in South Africa After Study Small clinical trial found that it doesn’t appear to protect recipients against mild and moderate illness from a fast-spreading new strain of the coronavirus"

References

1. Steinhauser, Gabriele (2021-02-07). "Rollout of AstraZeneca Covid-19 Vaccine Halted in South Africa After Study". Wall Street Journal. ISSN 0099-9660. Retrieved 2021-02-07.

Infobox vaccine type -: adenovirus vector or recombinant?

Anon IP's seem to be doing unsummarised edit wars on whether to to have vaccine-type as adenovirus vector or recombinant in Template:Infobox drug. Have we have a consensus view please. Don't just edit it in, put reasoning and gain consensus here first please. Thankyou.Djm-leighpark (talk) 00:39, 17 February 2021 (UTC)

Question, are there both adenovirus vector or recombinant is vaccine type or there different? 136.158.32.147 (talk) 02:02, 17 February 2021 (UTC)

Quick passing comment (not throughly checked): The WHO report currently in the external link classifies the type as recombinant which is a standard type mentioned in Template:Infobox drug (and covers a wide variety of vaccines). Adenovirus vector is I believe mentioned more widely(maybe not by WP:MEDRS sources though), and may not be straighforwardly wikilinked to/from recombinant from memory. Djm-leighpark (talk) 11:50, 17 February 2021 (UTC)

WHO calls it recombinant here but my understanding is that it's both. "Viral vector" means that a harmless virus like Ad5 is used to deliver the vaccine material into the target cell. "Recombinant" means that the DNA of the viral vector has been modified to invoke an immune response against covid, rather than against Ad5. The Oxford vaccine uses a simian virus (the viral vector) to deliver a spike protein coding sequence (the recombinant DNA) to the target cell. I believe in the context of covid vaccines "viral vector" and "recombinant" may mean the same thing. GA-RT-22 (talk) 18:18, 17 February 2021 (UTC)

@GA-RT-22 Yes, instead of discussing of the infobox, let's explain this into the #vaccine_platform section. ChAd is a DNA virus, following entry its DNA genes are transported to the cell nucleus to be transcripted into mRNA and translated by the cell's machinery. AZD1222 is replication defective: some essential adenoviral genes have been deleted and replaced by one coding for the spike, following entry of the *recombinant* virus its genes are transported to the cell nucleus thereby leading to the expression of the spike (eventually anchored onto the cell's surface, see this preprint), at this point it is the same for all approved vaccines: presentation of peptides on MHC-I, activation of T-cells, and the slightly more mysterious (cytotoxicity & phagocytosis against spike-expressing cells?) presentation on MHC-II on antigen presenting cells, which is the most desired effect, eventually transported to lymphoid organs and leading to B-cells/Th-cells affinity maturation of antibodies. 2A01:E0A:852:9590:6088:EC38:1F6E:EEA1 (talk) 23:58, 21 February 2021 (UTC)

Covishield in lead

@Whywhenwhohow: Hi, you reverted the inclusion of the market name Covishield in the lead, citing WP:MEDLEAD. Please could you indicate where in WP:MEDLEAD it indicates that common market names should not be included in the lead section - MOS:MED clearly states "alternative names may be specified in the lead" and that we should "use plain English" if possible. In almost all other cases (e.g. Ibuprofen, Pfizer–BioNTech COVID-19 vaccine, Trastuzumab) articles include names that drugs are commonly marketed under. Thus, there is an imperative to include Covishield in the lead using both precedence and the MOS. ArcMachaon (talk) 00:42, 9 March 2021 (UTC)

The articles for many other Covid-19 vaccines mention trade names in both the lead and the infobox. Articles for some medications write this information in a separate paragraph, which may make sense if the name is not widely used in the Anglosphere. --Fernando Trebien (talk) 19:23, 13 March 2021 (UTC)

Blood clots (help!)

Hi Wiki team, I found a link I think is the first mention of blood clots, the entire article is biased and probably not reliable, but may be the start of the rumours? Seems a non-western writer as well so motivation ??

https://laptrinhx.com/news/the-appalling-science-and-conflicts-of-interest-behind-the-oxford-astrazeneca-covid-19-vaccine-KlwKZpx/

Hope this may help in quelling the rumours 2404:4408:2365:D700:F97D:E3A4:B099:B60E (talk) 12:59, 16 March 2021 (UTC)

What we have is fine. The link you provide is to disinformation. Alexbrn (talk) 13:02, 16 March 2021 (UTC)

Astrazeneca Propaganda

It would be good to have third party sources here and not make this entire article a Astrazeneca advocacy piece. Looks a bit ridiculous - borderline North Korean. Huasteca (talk) 21:38, 16 March 2021 (UTC)

The article has over 200 references, only a handful of which are to AstraZeneca material, and for mundane claims so far as I can see. Alexbrn (talk) 01:31, 17 March 2021 (UTC)

The section on blood clots in both the summary and under "suspensions" almost entirely mirrors the British propaganda getting pushed heavily on social media and other platforms the past few days. This wikipedia article barely mentions that the concern is actually extremely rare types of blood clotting (low platelet levels and/or CVST), and accepts the inappropriate categorization of the reactions as generic blood clots. However, the resulting emphasis on the expected prevalence rate of normal blood clots from various entities is completely irrelevant and highly misleading.

Since the correct data is publicly available with very little effort, the persistence in ignoring the relevance of the subtype of the clots from people who should know better is highly suggestive of deliberate propaganda. But perhaps if too many external sources are nonsense, Misplaced Pages is helpless to exclude it and must pretend that that nonsense is factual, relevant, and authoritative. 86.83.81.68 (talk) 09:18, 17 March 2021 (UTC)

Sound like conspiracism to me. Sources for "British propaganda" would be required, and WP:MEDRS for any medical content. Misplaced Pages needs to be careful not to reflect misinformation. Alexbrn (talk) 10:22, 17 March 2021 (UTC)

You are free to add any content you want, but please remember to adhere to WP:MEDRS. Content that didn't follow the guidelines may be removed. SunDawn (talk) 01:32, 17 March 2021 (UTC)

Alexbrn Literally all of the sources related to health concerns are Astrazeneca or British government sources. There is a very clear bias in this article. It seems systemic and deliberate to not just me. Huasteca (talk) 12:07, 17 March 2021 (UTC)

• All unassessed articles
• C-Class COVID-19 articles
• Mid-importance COVID-19 articles
• WikiProject COVID-19 articles
• C-Class medicine articles
• Mid-importance medicine articles
• All WikiProject Medicine pages
• C-Class pharmacology articles
• Mid-importance pharmacology articles
• WikiProject Pharmacology articles
• Misplaced Pages articles under general sanctions